Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free SGHT Stock Alerts

Sight Sciences (SGHT) Competitors

Sight Sciences logo
$5.42 -0.42 (-7.19%)
Closing price 04:00 PM Eastern
Extended Trading
$5.42 0.00 (-0.09%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

SGHT vs. TNDM, CNMD, AORT, AVR, and DRTS

Should you buy Sight Sciences stock or one of its competitors? MarketBeat compares Sight Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sight Sciences include Tandem Diabetes Care (TNDM), CONMED (CNMD), Artivion (AORT), Anteris Technologies Global (AVR), and Alpha Tau Medical (DRTS). These companies are all part of the "medical equipment" industry.

How does Sight Sciences compare to Tandem Diabetes Care?

Sight Sciences (NASDAQ:SGHT) and Tandem Diabetes Care (NASDAQ:TNDM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

55.5% of Sight Sciences shares are owned by institutional investors. 28.9% of Sight Sciences shares are owned by insiders. Comparatively, 2.1% of Tandem Diabetes Care shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Sight Sciences currently has a consensus target price of $8.14, indicating a potential upside of 50.25%. Tandem Diabetes Care has a consensus target price of $29.13, indicating a potential upside of 93.01%. Given Tandem Diabetes Care's stronger consensus rating and higher probable upside, analysts clearly believe Tandem Diabetes Care is more favorable than Sight Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sight Sciences
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.44
Tandem Diabetes Care
1 Sell rating(s)
11 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.45

Tandem Diabetes Care has a net margin of -9.20% compared to Sight Sciences' net margin of -46.83%. Sight Sciences' return on equity of -52.34% beat Tandem Diabetes Care's return on equity.

Company Net Margins Return on Equity Return on Assets
Sight Sciences-46.83% -52.34% -28.49%
Tandem Diabetes Care -9.20%-53.88%-7.88%

In the previous week, Tandem Diabetes Care had 1 more articles in the media than Sight Sciences. MarketBeat recorded 2 mentions for Tandem Diabetes Care and 1 mentions for Sight Sciences. Sight Sciences' average media sentiment score of 1.87 beat Tandem Diabetes Care's score of 1.45 indicating that Sight Sciences is being referred to more favorably in the media.

Company Overall Sentiment
Sight Sciences Very Positive
Tandem Diabetes Care Positive

Sight Sciences has a beta of 2.41, indicating that its stock price is 141% more volatile than the broader market. Comparatively, Tandem Diabetes Care has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market.

Sight Sciences has higher earnings, but lower revenue than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Sight Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sight Sciences$77.36M3.81-$38.43M-$0.71N/A
Tandem Diabetes Care$1.01B1.02-$204.71M-$1.40N/A

Summary

Sight Sciences beats Tandem Diabetes Care on 9 of the 17 factors compared between the two stocks.

How does Sight Sciences compare to CONMED?

CONMED (NYSE:CNMD) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

CONMED has a net margin of 4.00% compared to Sight Sciences' net margin of -46.83%. CONMED's return on equity of 13.84% beat Sight Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
CONMED4.00% 13.84% 6.05%
Sight Sciences -46.83%-52.34%-28.49%

In the previous week, CONMED had 1 more articles in the media than Sight Sciences. MarketBeat recorded 2 mentions for CONMED and 1 mentions for Sight Sciences. Sight Sciences' average media sentiment score of 1.87 beat CONMED's score of 0.15 indicating that Sight Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
CONMED Neutral
Sight Sciences Very Positive

CONMED has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CONMED$1.37B0.72$47.06M$1.7718.46
Sight Sciences$77.36M3.81-$38.43M-$0.71N/A

CONMED currently has a consensus price target of $39.50, indicating a potential upside of 20.88%. Sight Sciences has a consensus price target of $8.14, indicating a potential upside of 50.25%. Given Sight Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Sight Sciences is more favorable than CONMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CONMED
2 Sell rating(s)
5 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.71
Sight Sciences
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.44

CONMED has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.41, indicating that its stock price is 141% more volatile than the broader market.

55.5% of Sight Sciences shares are held by institutional investors. 0.3% of CONMED shares are held by company insiders. Comparatively, 28.9% of Sight Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

CONMED and Sight Sciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Sight Sciences compare to Artivion?

Sight Sciences (NASDAQ:SGHT) and Artivion (NYSE:AORT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

Sight Sciences currently has a consensus target price of $8.14, suggesting a potential upside of 50.25%. Artivion has a consensus target price of $44.17, suggesting a potential upside of 96.03%. Given Artivion's stronger consensus rating and higher probable upside, analysts plainly believe Artivion is more favorable than Sight Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sight Sciences
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.44
Artivion
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75

Sight Sciences has a beta of 2.41, suggesting that its share price is 141% more volatile than the broader market. Comparatively, Artivion has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

Artivion has a net margin of 2.55% compared to Sight Sciences' net margin of -46.83%. Artivion's return on equity of 7.15% beat Sight Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Sight Sciences-46.83% -52.34% -28.49%
Artivion 2.55%7.15%3.63%

In the previous week, Artivion had 4 more articles in the media than Sight Sciences. MarketBeat recorded 5 mentions for Artivion and 1 mentions for Sight Sciences. Sight Sciences' average media sentiment score of 1.87 beat Artivion's score of 0.32 indicating that Sight Sciences is being referred to more favorably in the media.

Company Overall Sentiment
Sight Sciences Very Positive
Artivion Neutral

Artivion has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sight Sciences$77.36M3.81-$38.43M-$0.71N/A
Artivion$441.33M2.48$9.77M$0.2493.88

55.5% of Sight Sciences shares are held by institutional investors. Comparatively, 86.4% of Artivion shares are held by institutional investors. 28.9% of Sight Sciences shares are held by company insiders. Comparatively, 6.3% of Artivion shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Artivion beats Sight Sciences on 12 of the 16 factors compared between the two stocks.

How does Sight Sciences compare to Anteris Technologies Global?

Anteris Technologies Global (NASDAQ:AVR) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

55.5% of Sight Sciences shares are held by institutional investors. 4.5% of Anteris Technologies Global shares are held by company insiders. Comparatively, 28.9% of Sight Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Anteris Technologies Global has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.41, meaning that its share price is 141% more volatile than the broader market.

Anteris Technologies Global currently has a consensus price target of $16.00, indicating a potential upside of 62.44%. Sight Sciences has a consensus price target of $8.14, indicating a potential upside of 50.25%. Given Anteris Technologies Global's stronger consensus rating and higher probable upside, analysts plainly believe Anteris Technologies Global is more favorable than Sight Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anteris Technologies Global
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Sight Sciences
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.44

In the previous week, Anteris Technologies Global had 4 more articles in the media than Sight Sciences. MarketBeat recorded 5 mentions for Anteris Technologies Global and 1 mentions for Sight Sciences. Sight Sciences' average media sentiment score of 1.87 beat Anteris Technologies Global's score of 0.79 indicating that Sight Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
Anteris Technologies Global Positive
Sight Sciences Very Positive

Sight Sciences has a net margin of -46.83% compared to Anteris Technologies Global's net margin of -5,148.78%. Sight Sciences' return on equity of -52.34% beat Anteris Technologies Global's return on equity.

Company Net Margins Return on Equity Return on Assets
Anteris Technologies Global-5,148.78% -124.76% -101.21%
Sight Sciences -46.83%-52.34%-28.49%

Sight Sciences has higher revenue and earnings than Anteris Technologies Global. Sight Sciences is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anteris Technologies Global$1.85M518.00-$94.14M-$2.23N/A
Sight Sciences$77.36M3.81-$38.43M-$0.71N/A

Summary

Sight Sciences beats Anteris Technologies Global on 11 of the 16 factors compared between the two stocks.

How does Sight Sciences compare to Alpha Tau Medical?

Sight Sciences (NASDAQ:SGHT) and Alpha Tau Medical (NASDAQ:DRTS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

Sight Sciences has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Sight Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sight Sciences$77.36M3.81-$38.43M-$0.71N/A
Alpha Tau MedicalN/AN/A-$42.63M-$0.67N/A

Sight Sciences currently has a consensus target price of $8.14, indicating a potential upside of 50.25%. Alpha Tau Medical has a consensus target price of $12.60, indicating a potential upside of 0.16%. Given Sight Sciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Sight Sciences is more favorable than Alpha Tau Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sight Sciences
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.44
Alpha Tau Medical
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

Sight Sciences has a beta of 2.41, meaning that its share price is 141% more volatile than the broader market. Comparatively, Alpha Tau Medical has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market.

In the previous week, Alpha Tau Medical had 6 more articles in the media than Sight Sciences. MarketBeat recorded 7 mentions for Alpha Tau Medical and 1 mentions for Sight Sciences. Sight Sciences' average media sentiment score of 1.87 beat Alpha Tau Medical's score of 0.16 indicating that Sight Sciences is being referred to more favorably in the media.

Company Overall Sentiment
Sight Sciences Very Positive
Alpha Tau Medical Neutral

Alpha Tau Medical has a net margin of 0.00% compared to Sight Sciences' net margin of -46.83%. Sight Sciences' return on equity of -52.34% beat Alpha Tau Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Sight Sciences-46.83% -52.34% -28.49%
Alpha Tau Medical N/A -73.23%-52.90%

55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 2.7% of Alpha Tau Medical shares are owned by institutional investors. 28.9% of Sight Sciences shares are owned by insiders. Comparatively, 39.5% of Alpha Tau Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Sight Sciences beats Alpha Tau Medical on 11 of the 15 factors compared between the two stocks.

Get Sight Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for SGHT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGHT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SGHT vs. The Competition

Export
MetricSight SciencesMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$317.75M$7.31B$6.87B$12.45B
Dividend YieldN/A1.25%2.67%6.16%
P/E Ratio-7.6350.1227.5124.87
Price / Sales3.8180.49540.69102.84
Price / CashN/A26.2348.5358.59
Price / Book4.487.3611.016.54
Net Income-$38.43M$159.19M$3.57B$336.70M
7 Day Performance0.18%0.18%2.56%3.31%
1 Month Performance11.52%-5.16%0.89%1.68%
1 Year Performance31.23%4.62%36.84%31.96%

Sight Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SGHT
Sight Sciences
3.7394 of 5 stars		$5.42
-7.2%		$8.14
+50.3%		+35.8%$317.75M$77.36MN/A210
TNDM
Tandem Diabetes Care
3.505 of 5 stars		$14.41
+0.5%		$29.13
+102.1%		-16.4%$982.71M$1.01BN/A2,500
CNMD
CONMED
4.0306 of 5 stars		$33.77
+3.8%		$39.50
+17.0%		-33.7%$979.75M$1.37B19.083,900
AORT
Artivion
4.724 of 5 stars		$20.68
+2.7%		$44.17
+113.6%		-27.9%$977.17M$458.69M86.171,800
AVR
Anteris Technologies Global
3.157 of 5 stars		$10.28
+7.2%		$16.00
+55.6%		+140.9%$933.51M$1.91MN/A138

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SGHT) was last updated on 6/30/2026 by MarketBeat.com Staff.
From Our Partners
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
[Free Report] The 11-Hour Options Guide for Beginners - trade and ticker included
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The startup growing 23 times faster than Nvidia
An official SEC document contains a name Elon Musk revealed on page 146 - a startup that one analyst believes ...
Brownstone Research | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel